Endo Pharmaceuticals (ENDP) Receives Complete Response From FDA On FORTESTA
More News related to ENDP
- Endo Pharma (ENDP) Announces Settlement with LecTec Over Outstanding Patent Litigation
- Endo Pharmaceuticals and LecTec Settle Patent Dispute
- Endo Pharma (ENDP) Posts Q3 EPS of $0.63, Misses By 1c; Guides
- Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
More News related to FDA
- Prudential Bancorp of Penn. (PBIP) Swings to Q4 Profit
- Pharmasset (VRUS) Reports Inline Q4 Loss of $0.53
- Sterling Banks (STBK) Swings to Q3 Loss
- Highlights From DE's Q4 Conference Call: Production Will Pick Up in 2010, But Overall Conditions to Remain Fairly Restrained
- Highlights From TIF's Q3 Conference Call: Sales Declines, But Less-Than-Expected; Raises FY Outlook
Endo Pharmaceuticals (Nasdaq: ENDP) received a Complete Response letter from the FDA regarding the New Drug Application for FORTESTA 2% Gel for men diagnosed with low testosterone (Low T), also known as hypogonadism.
"The potential of this action was considered in the structure of the deal to in-license this product," said Dr. Ivan Gergel, M.D., executive vice president, R&D, Endo Pharmaceuticals. "We will continue to work closely with the FDA to address their questions and we expect to file a complete response, mid-2010. Endo is committed to bringing FORTESTA to market to offer men another option for testosterone replacement therapy."
Related Categories
FDAStocks Mentioned
+0.27Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
